Charles Schwab’s Biolase, Inc. BIOL Stock Holding History

Charles Schwab’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-24	Closed	-$23K	–	3633
2021 Q4	$23K	Hold	24	–	–	﹤0.01%	3577
2021 Q3	$38K	Hold	24	–	–	﹤0.01%	3478
2021 Q2	$42K	Hold	24	–	–	﹤0.01%	3393
2021 Q1	$50K	Buy	+24	New	+$59K	﹤0.01%	3437
2014 Q2	–	Sell	-4	Closed	-$111K	–	3147
2014 Q1	$111K	Hold	4	–	–	﹤0.01%	3030
2013 Q4	$130K	Hold	4	–	–	﹤0.01%	3036
2013 Q3	$91K	Hold	4	–	–	﹤0.01%	3040
2013 Q2	$162K	Buy	+4	New	+$224K	﹤0.01%	2976

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return

Charles Schwab's BIOL Position: Q1 2022 in Review

Charles Schwab sold out of Biolase, Inc. (BIOL) in Q1 2022, closing a stake of 24 shares — an estimated $23K sold.

Charles Schwab first reported a position in BIOL in Q2 2013 and held it in 8 quarters. The position peaked at $162K in Q2 2013. 28 funds tracked by Wall St. Rank hold BIOL as of Q1 2022.

Charles Schwab reported no remaining Biolase, Inc. position as of Q1 2022 after selling out during the quarter.
Charles Schwab sold 24 Biolase, Inc. shares in Q1 2022, an estimated $23K.
Charles Schwab first reported a position in Biolase, Inc. in Q2 2013 and held it in 8 quarters.
Charles Schwab's Biolase, Inc. position peaked at $162K in Q2 2013.
28 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.